ReviewNature reviews. Endocrinology2017
Endocrine-disrupting chemicals and fatty liver disease.
Review in Nature reviews. Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis.Environmental health perspectives · 2022Pooled it
- Effects of Pharmacological and Agrochemical Endocrine Disruptors on Human Sperm Mitochondrial Respiration: Evidence from Ex Vivo Bioenergetic Profiling.Journal of xenobiotics · 2026Article
- Direct exposure to vinclozolin induces sex-dependent mitochondrial dysfunction in mouse liver.Current research in toxicology · 2026Article
- Effects of an environmentally relevant mixture of organophosphate esters on the phenotype and function of HepG2 liver cells.Archives of toxicology · 2025Article
- Exploring the mechanism of PFTrDA on human hepatic metabolic diseases based on network toxicology and molecular docking.Scientific reports · 2025Article
- Uncovering Exposure Patterns of Metals, PFAS, Phthalates, and PAHs and Their Combined Effect on Liver Injury Markers.Journal of xenobiotics · 2025Article
- Perfluoroundecanoic Acid Inhibits Liver Cell Development in Pubertal Male Rats via Inducing Oxidative Stress.ACS omega · 2025Article
- Article
- Plasticity of Epigenomic and Transcriptomic Aging Reveals Common Targets for Reprogramming by Environmental Exposures.Research square · 2025Article
- MASLD in children: integrating epidemiological trends with mechanistic and translational advances.The Journal of clinical investigation · 2025Review
- Ancestral bisphenol A exposure led to non-alcoholic fatty liver disease and sex-specific alterations in proline and bile metabolism pathways in the liver.Environmental toxicology and chemistry · 2025Article
- Evaluation of FXR Activity in Pollutants Identified in Sewage Sludge and SubsequentEnvironmental health perspectives · 2025Article
- Consensus on the key characteristics of metabolism disruptors.Nature reviews. Endocrinology · 2025Review
- Impact of blood lead and manganese levels on metabolic dysfunction-associated steatotic liver disease prevalence: insights from NHANES (2017-2020).BMC gastroenterology · 2025Article
- Association between aspirin use and the risk of incident nonalcoholic fatty liver disease.European journal of epidemiology · 2025Article
- Recent advances in AI-based toxicity prediction for drug discovery.Frontiers in chemistry · 2025Review
- Bisphenols exposure and non-alcoholic fatty liver disease: from environmental trigger to molecular pathogenesis.Frontiers in endocrinology · 2025Review
- Overview of the hazardous impacts of metabolism-disrupting chemicals on the progression of fatty liver diseases.Molecular & cellular toxicology · 2025Article
- High Levels of Vitamin C Intake Modify Effects of Phthalates on Metabolic Dysfunction-associated Steatotic Liver Disease: A Nationally Representative Study.Journal of clinical and translational hepatology · 2024Article
- Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities.Intestinal research · 2024Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A growing epidemic of nonalcoholic fatty liver disease (NAFLD) is paralleling the increase in the incidence of obesity and diabetes mellitus in countries that consume a Western diet. As NAFLD can lead to life-threatening conditions such as cirrhosis and hepatocellular carcinoma, an understanding of the factors that trigger its development and pathological progression is needed. Although by definition this disease is not associated with alcohol consumption, exposure to environmental agents that have been linked to other diseases might have a role in the development of NAFLD. Here, we focus on one class of these agents, endocrine-disrupting chemicals (EDCs), and their potential to influence the initiation and progression of a cascade of pathological conditions associated with hepatic steatosis (fatty liver). Experimental studies have revealed several potential mechanisms by which EDC exposure might contribute to disease pathogenesis, including the modulation of nuclear hormone receptor function and the alteration of the epigenome. However, many questions remain to be addressed about the causal link between acute and chronic EDC exposure and the development of NAFLD in humans. Future studies that address these questions hold promise not only for understanding the linkage between EDC exposure and liver disease but also for elucidating the molecular mechanisms that underpin NAFLD, which in turn could facilitate the development of new prevention and treatment opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.